Answers are grounded in this paper and cite their sources.
INTRODUCTION: Brain exposure is a crucial consideration in the design and development of CNS-active drugs. It is a multifaceted objective, that requires careful optimization of physicochemical properties to achieve adequate brain penetration and sufficient unbound drug concentrations. AREAS COVERED: The authors review the different quantitative measures of brain exposure, including parameters describing brain distribution and those reflecting unbound drug concentrations. Furthermore, they discuss the evolution of quantitative structure-property relationship (QSPR) models for predicting and classifying brain exposure and the effect of efflux transporters on brain penetration. Recent publications were identified through searches of the PubMed database. Key physicochemical determinants for the different brain exposure parameters are highlighted, together with their optimal thresholds or recommended ranges as practical guidelines for CNS drug design. EXPERT OPINION: The contrasting effects of certain physicochemical properties on brain permeability and unbound brain concentrations highlight the need for an appropriate balance among these properties. In addition, transporter-mediated active efflux along with pharmacokinetic properties, target affinity, and safety endpoints, should be integrated in the optimization process. Future approaches should move toward integrated multi-objective optimization, combining these factors to identify compounds that achieve sufficient unbound drug concentrations at brain target sites while satisfying broader pharmacokinetic, safety, and drug-likeness requirements.
No takes yet. Share an insight, caveat, or question.
Vallianatou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: